790612-94-1

Usage

Uses

Used in Pharmaceutical Industry:
DL-2-PIPERIDINE-D9-CARBOXYLIC ACID is used as an active pharmaceutical ingredient for the development of drugs targeting the central nervous system. Its involvement in synaptic transmission makes it a potential candidate for the treatment of neurological disorders and mental health conditions.
Used in Research and Development:
DL-2-PIPERIDINE-D9-CARBOXYLIC ACID is used as a research compound in the field of neuroscience to study the mechanisms of synaptic transmission and the role of piperidine-based compounds in the central nervous system. This research can lead to the discovery of new therapeutic agents and a better understanding of neurological processes.
Used in Diagnostic Applications:
DL-2-PIPERIDINE-D9-CARBOXYLIC ACID is used as a diagnostic marker in the assessment of central nervous system function. Its presence and levels in biological samples can provide valuable information about the health and functioning of the brain and nervous system, aiding in the diagnosis of various neurological conditions.

Relevant academic research and scientific papers

Biosynthesis of pipecolic acid by RapL, a lysine cyclodeaminase encoded in the rapamycin gene cluster

Rapamycin, FK506, and FK520 are immunosuppressant macrolactone natural products comprised of predominantly polyketide-based core structures. A single nonproteinogenic pipecolic acid residue is installed into the scaffold by a nonribosomal peptide synthetase that also performs the subsequent macrocyclization step at the carbonyl group of this amino acid. It has been assumed that pipecolic acid is generated from lysine by the cyclodeaminases RapL/FkbL. Herein we report the heterologous overexpression and purification of RapL and validate its ability to convert L-lysine to L-pipecolic acid by a cyclodeamination reaction that involves redox catalysis. RapL also accepts L-ornithine as a substrate, albeit with a significantly reduced catalytic efficiency. Turnover is presumed to encompass a reversible oxidation at the α-amine, internal cyclization, and subsequent re-reduction of the cyclic Δ1-piperideine-2-carboxylate intermediate. As isolated, RapL has about 0.17 equiv of tightly bound NAD+, suggesting that the enzyme is incompletely loaded when overproduced in E. coli. In the presence of exogenous NAD+, the initial rate is elevated 8-fold with a K m of 2.3 μM for the cofactor, consistent with some release and rebinding of NAD+ during catalytic cycles. Through the use of isotopically labeled substrates, we have confirmed mechanistic details of the cyclodeaminase reaction, including loss of the α-amine and retention of the hydrogen atom at the α-carbon. In addition to the characterization of a critical enzyme in the biosynthesis of a medically important class of natural products, this work represents the first in vitro characterization of a lysine cyclodeaminase, a member of a unique group of enzymes which utilize the nicotinamide cofactor in a catalytic manner.